Ligand Pharmaceuticals Incorporated
Price Action
Technical Summary
STAGE 2 UPTRENDLigand Pharmaceuticals Incorporated is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 79), indicating performance broadly in line with the market. Earnings growth of 16% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $226.53 | +2.66% | ABOVE |
| 50 SMA | $213.08 | +9.14% | ABOVE |
| 100 SMA | $203.30 | +14.39% | ABOVE |
| 150 SMA | $199.42 | +16.61% | ABOVE |
| 200 SMA | $188.45 | +23.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LGND in an uptrend right now?
LGND has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, LGND is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is LGND overbought or oversold?
LGND's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is LGND outperforming the market?
LGND has a Relative Strength (RS) Rating of 79 out of 99. LGND is performing about average compared to the market.
Where is LGND in its 52-week range?
LGND is trading at $232.55, which is 94% of its 52-week high ($247.38) and 90% above its 52-week low ($98.89).
How volatile is LGND?
LGND has a Beta of 0.99 and 52-week volatility of 35%. It's less volatile than the S&P 500 - generally more stable.